EUVIMEDEUVIMED entdecken
Open Access

Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes

Elizabeth N Madva iD, Kyle Staller iD, Jeff C Huffman, Braden Kuo, Isabelle Garcia-Fischer, Micaela Atkins, Laurie Keefer, Christopher M Celano, Helen Burton Murray iD

Neurogastroenterology & Motility · 2023-02 · 35 (2)

DOI: 10.1111/nmo.14493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 13.11.2022. Verfasst von Elizabeth N Madva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Brain, Neurotransmitter Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known about the impact of psychiatric comorbidity on pharmacologic treatment outcomes, including neuromodulators (medications targeting the gut–brain axis), among adult patients with disorders of gut–brain interaction (DGBI). Accordingly, we aimed to examine associations between psychiatric comorbidity and DGBI pharmacologic treatment outcomes.

Methods

In a retrospective study of consecutively referred new patients ( N = 410; ages 18–90; 73% female) to a tertiary neurogastroenterology clinic in 2016 with follow‐up through 2018, relationships between psychiatric illness (any psychiatric illness, anxiety disorders, depressive disorders) and pharmacologic treatment selection (any medication, neuromodulating medication) and treatment outcomes, respectively, were examined using multivariable logistic regression, adjusting for demographics, gastrointestinal (GI) diagnoses, and pre‐existing neuromodulator use. Key Results Anxiety disorders (35%) were the most common psychiatric comorbidity, followed by depressive disorders (29%). Patients with anxiety disorders were more likely to be prescribed a neuromodulator by their gastroenterologist (OR = 1.72 [95% CI 1.10–2.75]) yet less likely to respond to neuromodulators (OR = 0.43 [0.21–0.90]) or any GI medication (OR = 0.24 [0.12–0.50]) in fully adjusted analyses. In contrast, depressive disorders were not associated with neuromodulator prescription or response. Conclusions and Inferences Anxiety disorders are common among patients with DGBI and significantly reduce the likelihood of GI pharmacologic treatment response to any medication prescribed, including neuromodulators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrainNeurotransmitter AgentsHumansAdultFemaleAdolescentYoung AdultMiddle AgedAgedAged, 80 and overMaleRetrospective StudiesPrevalenceComorbidityTreatment Outcome

Stichwörter der Autor:innen

functional gastrointestinal disordersgastrointestinal diseasesgastrointestinal motilityneuromodulatorspharmacologypsychosomatic medicine

Substanzen

Neurotransmitter Agents

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Center for Neurointestinal Health, Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Mt. Sinai Hospital, Psychiatry and Gastroenterology, New York, New York, USA.

ORCID-Profile: Elizabeth N Madva, Kyle Staller, Helen Burton Murray

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Heart, Lung, and Blood Institute
  • Harvard Medical School

Zitieren

APA

Madva, E. N., Staller, K., Huffman, J. C., Kuo, B., Garcia-Fischer, I., Atkins, M., Keefer, L., Celano, C. M., & Murray, H. B. (2023). Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes. Neurogastroenterology & Motility, 35(2). https://doi.org/10.1111/nmo.14493

Vancouver

Madva EN, Staller K, Huffman JC, Kuo B, Garcia-Fischer I, Atkins M, et al. Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes. Neurogastroenterology & Motility. 2023;35(2). doi:10.1111/nmo.14493

BibTeX
@article{Madva2023,
  author = {Madva, Elizabeth N and Staller, Kyle and Huffman, Jeff C and Kuo, Braden and Garcia-Fischer, Isabelle and Atkins, Micaela and Keefer, Laurie and Celano, Christopher M and Murray, Helen Burton},
  title = {Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes},
  journal = {Neurogastroenterology & Motility},
  year = {2023},
  volume = {35},
  number = {2},
  doi = {10.1111/nmo.14493}
}
Kostenlos starten →